<DOC>
	<DOCNO>NCT00690963</DOCNO>
	<brief_summary>Patients inoperable non-small cell lung cancer presently treat chemotherapy radiation therapy . Despite combined approach , vast majority patient cancer recur treatment . A recurrence curable time . Because sensitivity surround structure chest irradiation , possible give radiation dose cure many tumor . Intensity-modulated radiation therapy special form radiotherapy delivery allow doctor reduce amount radiation dose normal tissue therefore reduce side effect . The reduction radiation side effect may allow radiation deliver tumor , therefore improve tumor control possibly longevity patient . The purpose study determine whether combination custom design intensity-modulated radiotherapy ( base individual tumor anatomy ) regular chemotherapy , safe enough allow intensification radiation treatment .</brief_summary>
	<brief_title>Individual Boosting Non-Small Cell Lung Cancer Using Hypofractionation , Intensity-modulated Radiation Therapy Respiratory Gating</brief_title>
	<detailed_description>All patient must satisfactory IMRT plan prior start radiation therapy , commence concurrently chemotherapy . All patient treat minimum 48 Gy 20 daily fraction 4 week [ 2.4 Gy per fraction ( fx ) ] , plan target volume ( PTV ) define pre chemotherapy CT PET image . This approximately biologically equivalent dose 54 Gy 27 # ( 5 fractions/week ) . A differential boosting select one 5 dose escalation scheme . The total individual radiotherapy dose prescribe accord high dose level satisfy set radiotherapy planning constraint individual 's anatomy . The trial proceed 2 phase . In first phase first 3 dose escalation schedule use . Once 3 schedule deem safe dose level 4 5 open participation .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients histologicallyproven , biopsy cytology , unresected lung cancer follow histologic type : Squamous cell carcinoma , Adenocarcinoma , Undifferentiated large cell carcinoma , NonSmall cee ; otherwise specify ( NOS , diagnosis cytology alone ) Patients AJCC Stage II , IIIA IIIB detectable tumour encompass radiation therapy field , include primary tumor involve regional lymph node Patient must deem suitable undergo definitive chemoradiotherapy treat Physician . Age &gt; = 18 ECOG/Zubrod status 01 Patients must measurable disease CT image Satisfactory granulocyte , platelet , bilirubin , AST calculate creatinine clearance Dose volume constraint must meet Patient must able use breathheld technique Patients undergone complete subtotal tumour resection Patients postresection intrathoracic tumour recurrence Patients eligible definitive surgery Evidence small cell histology Prior concurrent malignancy except nonmelanomatous skin cancer unless diseasefree least 5 year Exudative pleural effusion , pleural effusion positive cytology . Minimal pleural effusion small safely tap ( i.e . visible chest xray ) eligible . Patients myocardial infarction within precede 6 month symptomatic heart disease , include angina , congestive heart failure uncontrolled arrhythmias Pregnant woman ineligible . Patients childbearing potential must practice appropriate contraception Patients FEV1 &lt; = 0.8 . Patients FEV1 &gt; 0.8 &lt; 1.0 discussed Respiratory Physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Intensity-Modulated</keyword>
	<keyword>Dose Fractionation</keyword>
</DOC>